Insider trade

Harvard Bioscience (HBIO): CEO bought ~$25K

John D Duke, CEO at Harvard Bioscience, bought ~$25K of Harvard Bioscience shares.

~$25K
Approx. value · 5,000 sh @ $5.01
105K
Holds after · shares reported
Traded
Mar 16, 2026
Filed
Mar 17, 2026

What stands out in this filing

  • 3 HBIO insiders bought within the same week. That happened 5 times before in filings since 2006, most recently Dec 2008.
  • The first open-market purchase by any HBIO insider since Jun 2024.
  • John D Duke's first open-market purchase of HBIO in filings since 2006.
  • The purchase added 5.0% to the shares this insider held before it; the filing reports 105,000 shares afterwards.
  • 5,000 shares at an average of $5.01 each, as reported on the form.
  • 3 other insiders at HBIO also bought in the open market within 30 days.

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 12, 2025Federal contract · $258K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $258K obligated to date
  2. Dec 15, 2025Federal contract · $23K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $23K obligated to date
  3. Jan 14, 2026Federal contract · $22K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $22K obligated to date
  4. Jan 19, 2026Company filing · Form 8-K · Bylaws or charterChanged its bylaws, charter or fiscal year
  5. Jan 23, 2026Company filing · Form 8-K · Restructuring, Reg FDAnnounced job cuts, closures or a restructuring, and shared information with investors“On January 23, 2026, the Board of Directors of Harvard Bioscience, Inc. (the “Company”) approved management’s comprehensive plan, referred to as Project Viking, for the strategic consolidation of its manufacturing operations to improve efficiency and support long-term growth.”
  6. Feb 10, 2026Company filing · Form 8-K · ResultsReported its results
  7. Mar 6, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On March 6, 2026, Harvard Bioscience, Inc. (the “Company”) entered into an Amended and Restated Employment Agreement (the “Duke Employment Agreement”) with John Duke, the Company’s Chief Executive Officer.”
  8. Mar 12, 2026Company filing · Form 8-K · ResultsReported its results
  9. Mar 16, 2026 · this disclosureInsider · 3 insiders in a week, 6th time since 2006CEO purchased ~$25K of HBIO shares in the open market

What came next

  1. Mar 16, 2026Insider · 2 peopleInsiders: 2 purchases (~$87K)
  2. Mar 17, 2026Insider · 2 peopleInsiders: 2 purchases (~$90K)
  3. May 12, 2026Company filing · Form 8-K · ResultsReported its results
  4. Jun 2, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote“On June 2, 2026, the stockholders of Harvard Bioscience, Inc. (the “ Company ”) voted to approve the Amended and Restated 2021 Incentive Plan at the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
  5. Jun 9, 2026Federal contract · $653K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $653K obligated to date
  6. Jun 12, 2026Federal contract · $61K obligatedDepartment of Defense awarded HARVARD BIOSCIENCE INC: $61K obligated to date
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Harvard Bioscience

For Harvard Bioscience, OQRO holds 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HBIO page.

How this filing works

Explore the data

Common questions

Which Harvard Bioscience (HBIO) insider traded, and how much?

John D Duke, CEO at Harvard Bioscience, bought ~$25K of Harvard Bioscience shares. 5,000 shares at $5.01, open market.

When did it happen, and when was it made public?

Traded: Mar 16, 2026. Filed: Mar 17, 2026. That is 1 day between the two dates.

What stands out in this filing?

3 HBIO insiders bought within the same week. That happened 5 times before in filings since 2006, most recently Dec 2008. The first open-market purchase by any HBIO insider since Jun 2024. John D Duke's first open-market purchase of HBIO in filings since 2006.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Harvard Bioscience recently?

For Harvard Bioscience, OQRO holds 2 federal contract awards dated in the last 90 days. They are listed on the HBIO page.

Does this mean HBIO stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Harvard Bioscience

Everything OQRO holds on this company is on its HBIO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data